<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:06:47Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8886955" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8886955</identifier>
        <datestamp>2022-03-02</datestamp>
        <setSpec>ajrccm</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="letter">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Am J Respir Crit Care Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Am J Respir Crit Care Med</journal-id>
              <journal-id journal-id-type="publisher-id">ajrccm</journal-id>
              <journal-title-group>
                <journal-title>American Journal of Respiratory and Critical Care Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1073-449X</issn>
              <issn pub-type="epub">1535-4970</issn>
              <publisher>
                <publisher-name>American Thoracic Society</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8886955</article-id>
              <article-id pub-id-type="pmcid">PMC8886955</article-id>
              <article-id pub-id-type="pmc-uid">8886955</article-id>
              <article-id pub-id-type="pmid">34874818</article-id>
              <article-id pub-id-type="publisher-manuscript">202110-2279LE</article-id>
              <article-id pub-id-type="doi">10.1164/rccm.202110-2279LE</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Correspondence</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Rapid Phospholipid Turnover after Surfactant Nebulization in Severe COVID-19 Infection: A Randomized Clinical Trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7361-0756</contrib-id>
                  <name>
                    <surname>Postle</surname>
                    <given-names>Anthony D.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cor1" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7354-2028</contrib-id>
                  <name>
                    <surname>Clark</surname>
                    <given-names>Howard W.</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6527-2363</contrib-id>
                  <name>
                    <surname>Fink</surname>
                    <given-names>Jim</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Madsen</surname>
                    <given-names>Jens</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1761-969X</contrib-id>
                  <name>
                    <surname>Koster</surname>
                    <given-names>Grielof</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Panchal</surname>
                    <given-names>Madhuriben</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6039-5612</contrib-id>
                  <name>
                    <surname>Djukanovic</surname>
                    <given-names>Ratko</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1982-3379</contrib-id>
                  <name>
                    <surname>Brealey</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9484-7581</contrib-id>
                  <name>
                    <surname>Grocott</surname>
                    <given-names>Michael P. W.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0165-3359</contrib-id>
                  <name>
                    <surname>Dushianthan</surname>
                    <given-names>Ahilanandan</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>University of Southampton<break/>Southampton, United Kingdom</aff>
                <aff id="aff2"><label><sup>2</sup></label>University Hospital Southampton National Health System Foundation Trust<break/>Southampton, United Kingdom</aff>
                <aff id="aff3"><label><sup>3</sup></label>University College London Hospital<break/>London, United Kingdom</aff>
                <aff id="aff4"><label><sup>4</sup></label>University College London Hospital Biomedical Research Centre<break/>London, United Kingdom</aff>
                <aff id="aff5"><label><sup>5</sup></label>Aerogen Pharma Corporation<break/>San Mateo, California</aff>
                <aff id="aff6"><label><sup>6</sup></label>University College London<break/>London, United Kingdom</aff>
                <aff id="aff7"><label><sup>7</sup></label>University College Hospitals London<break/>London, United Kingdom</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><label>*</label>Corresponding author (e-mail: <email xlink:href="mailto:adp@soton.ac.uk">adp@soton.ac.uk</email>).</corresp>
              </author-notes>
              <pub-date date-type="pub" publication-format="electronic">
                <day>7</day>
                <month>12</month>
                <year>2021</year>
              </pub-date>
              <pub-date date-type="collection" publication-format="electronic">
                <day>15</day>
                <month>2</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>7</day>
                <month>12</month>
                <year>2021</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>205</volume>
              <issue>4</issue>
              <fpage>471</fpage>
              <lpage>473</lpage>
              <permissions>
                <copyright-statement>Copyright Â© 2022 by the American Thoracic Society</copyright-statement>
                <copyright-year>2022</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This article is open access and distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="rccm.202110-2279LE.pdf"/>
              <related-object object-id="10.1164/rccm.202110-2279LE_discussion" object-id-type="doi" object-type="discussion" id="ro2279LE"/>
              <funding-group specific-use="FundRef">
                <award-group award-type="grant">
                  <funding-source country="US">
                    <institution-wrap>
                      <institution>Bill &amp; Melinda Gates Foundation</institution>
                      <institution-id institution-id-type="doi">10.13039/100000865</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>COVID-19 Aerosolized Surfactant Clinical Trial</award-id>
                </award-group>
                <award-group award-type="grant">
                  <funding-source country="UK">
                    <institution>National Institute of Health Research (NIHR)</institution>
                  </funding-source>
                  <award-id>NIHR Southampton Biomedical Research Centre</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="1"/>
                <ref-count count="9"/>
                <page-count count="3"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p content-type="flushleft"><italic>To the Editor</italic>:</p>
            <p content-type="flushleft">The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus targets the ACE-2 receptor on type II alveolar epithelial (ATII) cells. ATII cells synthesize and secrete lung surfactant, and surfactant deficiency consequent of ATII cell dysfunction may contribute to progression to acute respiratory distress syndrome (ARDS) in coronavirus disease (COVID-19), but this has yet to be confirmed (<xref rid="bib1" ref-type="bibr">1</xref>). Several clinical trials of surfactant for COVID-19 ARDS are ongoing, but there is a critical need to optimize dose concentration, dose frequency and duration, and mode of delivery of therapeutic surfactant administration. In this pilot study, we evaluated the effectiveness of a prototype breath-synchronized vibrating mesh nebulizer to deliver exogenous surfactant to patients ventilated for severe COVID-19 infection (<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>) and report here endogenous surfactant status, turnover, and half-life of administered surfactant.Â These results have not been previously reported in abstract form.</p>
            <sec sec-type="methods" disp-level="2">
              <title>Methods</title>
              <p content-type="flushleft">Patients (<italic>n</italic>â=â10) were recruited within 24 hours of endotracheal intubation into a randomized control trial of nebulized surfactant in patients with COVID-19 ARDS (Clinical Trials number: NCT04362059) and were randomized 3:2 for surfactant and control arms. Results were compared with historic healthy control data (<xref rid="bib4" ref-type="bibr">4</xref>). Surfactant was nebulized by an investigational vibrating mesh breath-actuated aerosol system (Aerogen Pharma), controlled by a flow sensor in the inspiratory limb of the ventilation circuit (<xref rid="bib3" ref-type="bibr">3</xref>). Six patients were randomly allocated to receive three doses of 1,080 mg of Alveofact, a bovine surfactant widely used in preterm neonates (<xref rid="bib5" ref-type="bibr">5</xref>), at Tâ=â0, 8, and 24 hours. Tracheal aspirates were taken at 0, 8, 16, 24, 48, and 72 hours. Phospholipids were analyzed by electrospray ionization mass spectrometry (<xref rid="bib6" ref-type="bibr">6</xref>). Results are presented as medians and interquartile ranges, with statistical significance determined by the Mann-Whitney test.</p>
            </sec>
            <sec sec-type="results" disp-level="2">
              <title>Results</title>
              <p content-type="flushleft">Phospholipid analysis of baseline tracheal aspirates indicated that pulmonary surfactant was significantly compromised in patients ventilated for COVID-19 infection, with dipalmitoylphosphatidylcholine, the major surface-active component, being considerably reduced for all 10 patients (25.0, 20.9â29.4%) compared with healthy volunteers (46.8, 39.0â49.4% total phosphatidylcholine; <italic>P</italic>â&lt;â0.001) (data recalculated from reference [<xref rid="bib4" ref-type="bibr">4</xref>]). Although phospholipid compositions were identical between COVID-19 control and surfactant groups at baseline (<xref rid="tbl1" ref-type="table">Table 1</xref>), initial concentrations of total phosphatidylcholine and phosphatidylglycerol, typically enriched in surfactant, were significantly lower than in Alveofact and healthy control groups (<xref rid="bib4" ref-type="bibr">4</xref>) with corresponding increased concentrations of phospholipids characteristic of cell membranes such as phosphatidylserine and sphingomyelin (SM). The significant elevation of SM in tracheal aspirates from patients at Tâ=â0 hours compared with Alveofact (10.5, 8.2â12.1, vs. 1.2, 1.0â1.3%; <italic>P</italic>â&lt;â0.01) provided a basis for calculation of exogenous surfactant turnover. Importantly for turnover calculations, sphingomyelin fractional concentration remained relatively constant over the study period in the control group (<xref rid="tbl1" ref-type="table">Table 1</xref>). By contrast, aspirate phospholipid composition after surfactant nebulization changed substantially to resemble that of Alveofact. Phosphatidylcholine concentration doubled from 39.8% to 79% at Tâ=â8 hours, phosphatidylglycerol increased from 3.1 to 13.9% at Tâ=â16 hours, and all other phospholipid classes substantially declined. These changes gradually reversed with time, such that by 72 hours, phosphatidylcholine concentration was 59.4%, phosphatidylserine was 9.1%, and SM was 5.3%, reflecting decreased concentration of exogenous surfactant. The wide variation of absolute aspirate phospholipid concentration owing to variable recovery precluded its use for turnover calculation. Instead, exogenous surfactant turnover was determined relative to that of endogenous lipid in tracheal aspirates, based on the assumption that concentration and composition of endogenous lipid did not change substantially over the 72-hour study period. Alveofact turnover was calculated from the reciprocal of the percentage concentration of palmitoylsphingomyelin (SM16:0) as a marker of endogenous lipid. This value was maximal for all patients between Tâ=â8 and Tâ=â16 hours and returned toward baseline values by Tâ=â72 hours (<xref rid="fig1" ref-type="fig">Figure 1</xref>, solid circles). Kinetic models of these data were constructed by superimposing three first-order exponential decay curves at Tâ=â0, Tâ=â8, and Tâ=â24 hours (<xref rid="fig1" ref-type="fig">Figure 1</xref>, solid squares), assuming equal amounts of Alveofact were delivered at each nebulization, with good agreement between measured and modeled values. The model indicated the median estimated half-life for Alveofact phospholipid was 7.6 hours (range, 1.8â20.8 h) in these six surfactant-treated patients.</p>
              <table-wrap position="float" id="tbl1">
                <label>
Table 1.
</label>
                <caption>
                  <p>Concentration of Selected Phospholipid Classes in Tracheal Aspirate Samples over the 72-Hour Study Period for Control and Surfactant-treated Patients</p>
                </caption>
                <!--OASIS TABLE HERE-->
                <table frame="hsides" rules="groups">
                  <colgroup>
                    <col align="left"/>
                    <col align="center"/>
                    <col align="center"/>
                    <col align="center"/>
                    <col align="center"/>
                  </colgroup>
                  <thead>
                    <tr valign="bottom">
                      <th align="left" valign="bottom">Â </th>
                      <th align="center" valign="bottom">Phosphatidylcholine (<italic>%</italic>)</th>
                      <th align="center" valign="bottom">Phosphatidylglycerol (<italic>%</italic>)</th>
                      <th align="center" valign="bottom">Phosphatidylserine (<italic>%</italic>)</th>
                      <th align="center" valign="bottom">Sphingomyelin (<italic>%</italic>)</th>
                    </tr>
                  </thead>
                  <tbody valign="top">
                    <tr>
                      <td align="left">Alveofact composition (<italic>n</italic>â=â<italic>4</italic>)</td>
                      <td align="center">80.4 (8.0â81.2)</td>
                      <td align="center">10.8 (8.5â11.4)</td>
                      <td align="center">0.8 (0.4â4.3)</td>
                      <td align="center">1.2 (1.0â1.3)</td>
                    </tr>
                    <tr>
                      <td align="left">Control group (<italic>n</italic>â=â<italic>4</italic>)</td>
                      <td align="center">Â </td>
                      <td align="center">Â </td>
                      <td align="center">Â </td>
                      <td align="center">Â </td>
                    </tr>
                    <tr>
                      <td align="left">â0 h</td>
                      <td align="center">48.0 (32.1â56.8)</td>
                      <td align="center">2.2 (1.2â3.9)</td>
                      <td align="center">22.6 (17.0â30.6)</td>
                      <td align="center">9.8 (7.9â11.8)</td>
                    </tr>
                    <tr>
                      <td align="left">â8 h</td>
                      <td align="center">48.5 (29.5â60.2)</td>
                      <td align="center">4.2 (3.3â6.7)</td>
                      <td align="center">18.0 (10.9â24.7)</td>
                      <td align="center">9.1 (8.6â13.7)</td>
                    </tr>
                    <tr>
                      <td align="left">â16 h</td>
                      <td align="center">38.0 (27.8â53.6)</td>
                      <td align="center">2.7 (1.8â3.2)</td>
                      <td align="center">17.3 (16.7â24.9)</td>
                      <td align="center">9.0 (7.9â12.5)</td>
                    </tr>
                    <tr>
                      <td align="left">â24 h</td>
                      <td align="center">34.1 (17.1â56.7)</td>
                      <td align="center">3.5 (2.5â4.7)</td>
                      <td align="center">20.5 (14.8â34.0)</td>
                      <td align="center">10.4 (8.4â11.7)</td>
                    </tr>
                    <tr>
                      <td align="left">â48 h</td>
                      <td align="center">38.7 (20.2â513)</td>
                      <td align="center">3.3 (1.5â6.0)</td>
                      <td align="center">27.0 (16.4â44.0)</td>
                      <td align="center">10.9 (7.8â13.9)</td>
                    </tr>
                    <tr>
                      <td align="left">â72 h</td>
                      <td align="center">35.4 (26.2â49.3)</td>
                      <td align="center">2.1 (1.3â4.3)</td>
                      <td align="center">32.4 (24.4â33.9)</td>
                      <td align="center">11.8 (7.1â15.8)</td>
                    </tr>
                    <tr>
                      <td align="left">Surfactant-treated group (<italic>n</italic>â=â<italic>6</italic>)</td>
                      <td align="center">Â </td>
                      <td align="center">Â </td>
                      <td align="center">Â </td>
                      <td align="center">Â </td>
                    </tr>
                    <tr>
                      <td align="left">â0 h</td>
                      <td align="center">39.8 (29.8â52.3)</td>
                      <td align="center">3.1 (2.2â4.8)</td>
                      <td align="center">23.5 (11.2â25.9)</td>
                      <td align="center">10.9 (8.2â13.0)</td>
                    </tr>
                    <tr>
                      <td align="left">â8 h</td>
                      <td align="center">79.0 (75.4â84.8)</td>
                      <td align="center">11.7 (8.0â13.9)</td>
                      <td align="center">1.2 (0.9â1.9)</td>
                      <td align="center">2.0 (1.3â2.4)</td>
                    </tr>
                    <tr>
                      <td align="left">â16 h</td>
                      <td align="center">76.4 (68.3â79.1)</td>
                      <td align="center">13.9 (8.0â16.1)</td>
                      <td align="center">1.1 (0.8â2.2)</td>
                      <td align="center">1.9 (1.2â2.7)</td>
                    </tr>
                    <tr>
                      <td align="left">â24 h</td>
                      <td align="center">75.9 (61.3â79.4)</td>
                      <td align="center">11.9 (8.0â13.3)</td>
                      <td align="center">1.5 (1.3â8.6)</td>
                      <td align="center">3.0 (2.1â4.6)</td>
                    </tr>
                    <tr>
                      <td align="left">â48 h</td>
                      <td align="center">67.8 (54.5â73.4)</td>
                      <td align="center">10.1 (8.2â11.2)</td>
                      <td align="center">7.0 (2.5â12.2)</td>
                      <td align="center">3.7 (2.5â5.1)</td>
                    </tr>
                    <tr>
                      <td align="left">â72 h</td>
                      <td align="center">59.4 (44.2â68.9)</td>
                      <td align="center">9.8 (5.0â11.8)</td>
                      <td align="center">9.7 (5.4â21.6)</td>
                      <td align="center">5.3 (4.6â7.2)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="TF1">
                    <p>Data are presented as median (interquartile range).</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <fig position="float" id="fig1">
                <label>
Figure 1.
</label>
                <caption>
                  <p>Alveofact turnover in tracheal aspirate samples. An index of exogenous surfactant was calculated as the reciprocal of the percentage concentration of palmitoylsphingomeyelin (SM16:0), the predominant sphingomyelin species that was taken as a marker of endogenous phospholipid. The solid circles represent the measured data, whereas the solid squares are the modeled data generated by fitting an iterative kinetic model of three sequential exponential decay curves (meanâÂ±âSEM).</p>
                </caption>
                <graphic xlink:href="rccm.202110-2279LEf1" position="float"/>
              </fig>
            </sec>
            <sec sec-type="discussion" disp-level="2">
              <title>Discussion</title>
              <p content-type="flushleft">This is the first study to evaluate exogenous surfactant pharmacokinetics in patients with COVID-19; the rapid turnover of administered surfactant has direct implications for design of surfactant therapy trials in both patients with COVID-19 and those with other ARDS. It may help clarify why the transient improved oxygenation in most adult ARDS studies after surfactant supplementation was not sustained (<xref rid="bib7" ref-type="bibr">7</xref>). Our findings support the hypothesis that pulmonary surfactant deficiency may play an important role in patients mechanically ventilated for severe COVID-19. This is the first detailed analysis of phospholipid compositional changes after administration of a therapeutic dose of exogenous surfactant to any patient group; it sampled tracheal aspirates instead of BAL to minimize health careâassociated infections and prevent patient desaturation during frequent bronchoscopy. The novel methodology to estimate turnover based on the different lipid profiles of Alveofact and tracheal aspirates was analogous to the lecithin to sphingomyelin ratio (<xref rid="bib8" ref-type="bibr">8</xref>) and rested on the assumption that endogenous phospholipid concentration was constant over 72 hours in the treatment group but was diluted by exogenous surfactant. Importantly, although the index of surfactant turnover was not a direct measure of exogenous surfactant concentration, as the upper value is set by the concentration of SM16:0 in Alveofact, it enabled iterative kinetic modeling to estimate half-life from three first-order exponential decay curves superimposed at Tâ=â0, Tâ=â8, and Tâ=â24 hours. The resultant modeling of the Alveofact index was a reasonable fit to the measured data (<xref rid="fig1" ref-type="fig">Figure 1</xref>) and indicated a rapid turnover of exogenous surfactant in the airways and presumably the alveolus, such that little material remained at Tâ=â72 hours. This data will be correlated with clinical variables in a future substantive report. This conclusion broadly agrees with the one other report of surfactant kinetics in patients with ARDS, which followed the loss of surfactant labeled with a tracer amount of <sup>13</sup>C-palmitate in dipalmitoylphosphatidylcholine (<xref rid="bib9" ref-type="bibr">9</xref>). This rapid turnover of exogenous surfactant may be one contributor to the failure of clinical trials of surfactant therapy in ARDS, in addition to the heterogeneity of the patient population and multiple initiating factors. Our results suggest that more individualized and prolonged surfactant administration may be required to give time for recovery of the lungs in severe COVID-19.</p>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="supported-by">
                <p>Supported by the Bill &amp; Melinda Gates Foundation (INV-016631; COVID-19 Aerosolized Surfactant Clinical Trial). The National Institute of Health Research (NIHR) Southampton Biomedical Research Centre provided mass spectrometry facilities and salary support for G.K. and M.P. M.P.W.G. received part of his funding through the NIHR Senior Investigator Scheme. R.D. and M.P.W.G. received part of their funding through the NIHR Southampton Biomedical Research Centre. H.W.C. and D.B. received part of their funding through the NIHR University College London Hospital Biomedical Research Centre.</p>
              </fn>
              <fn>
                <p>Originally Published in Press as DOI: <ext-link xlink:href="https://doi.org/10.1164/rccm.202110-2279LE" ext-link-type="uri">10.1164/rccm.202110-2279LE</ext-link> on December 7, 2021</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><underline><bold><ext-link xlink:href="http://www.atsjournals.org/doi/suppl/10.1164/rccm.202110-2279LE/suppl_file/disclosures.pdf" ext-link-type="uri">Author disclosures</ext-link></bold></underline> are available with the text of this letter at <ext-link xlink:href="http://www.atsjournals.org" ext-link-type="uri">www.atsjournals.org</ext-link>.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bib1">
                <label>1.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mason</surname>
                      <given-names>RJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Thoughts on the alveolar phase of COVID-19</article-title>
                  <source>
                    <italic>Am J Physiol Lung Cell Mol Physiol</italic>
                  </source>
                  <year>2020</year>
                  <volume>319</volume>
                  <fpage>L115</fpage>
                  <lpage>L120</lpage>
                  <pub-id pub-id-type="pmid">32493030</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib2">
                <label>2.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Anzueto</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Baughman</surname>
                      <given-names>RP</given-names>
                    </name>
                    <name>
                      <surname>Guntupalli</surname>
                      <given-names>KK</given-names>
                    </name>
                    <name>
                      <surname>Weg</surname>
                      <given-names>JG</given-names>
                    </name>
                    <name>
                      <surname>Wiedemann</surname>
                      <given-names>HP</given-names>
                    </name>
                    <name>
                      <surname>RaventÃ³s</surname>
                      <given-names>AA</given-names>
                    </name>
                    <etal>
                      <italic>etÂ al.</italic>
                    </etal>
                    <collab>Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group</collab>
                  </person-group>
                  <article-title>Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>1996</year>
                  <volume>334</volume>
                  <fpage>1417</fpage>
                  <lpage>1421</lpage>
                  <pub-id pub-id-type="pmid">8618579</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib3">
                <label>3.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>DiBlasi</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Kajimoto</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Poli</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Deutsch</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Pfeiffer</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Zimmerman</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>
                      <italic>etÂ al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Breath-synchronized nebulized surfactant in a porcine model of acute respiratory distress syndrome</article-title>
                  <source>
                    <italic>Crit Care Explor</italic>
                  </source>
                  <year>2021</year>
                  <volume>3</volume>
                  <fpage>e0338</fpage>
                  <pub-id pub-id-type="pmid">33604579</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib4">
                <label>4.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dushianthan</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Goss</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Cusack</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Grocott</surname>
                      <given-names>MP</given-names>
                    </name>
                    <name>
                      <surname>Postle</surname>
                      <given-names>AD</given-names>
                    </name>
                  </person-group>
                  <article-title>Phospholipid composition and kinetics in different endobronchial fractions from healthy volunteers</article-title>
                  <source>
                    <italic>BMC Pulm Med</italic>
                  </source>
                  <year>2014</year>
                  <volume>14</volume>
                  <fpage>10</fpage>
                  <pub-id pub-id-type="pmid">24484629</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib5">
                <label>5.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Griese</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Dietrich</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Reinhardt</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Pharmacokinetics of bovine surfactant in neonatal respiratory distress syndrome</article-title>
                  <source>
                    <italic>Am J Respir Crit Care Med</italic>
                  </source>
                  <year>1995</year>
                  <volume>152</volume>
                  <fpage>1050</fpage>
                  <lpage>1054</lpage>
                  <pub-id pub-id-type="pmid">7663782</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib6">
                <label>6.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Madsen</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Panchal</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Mackay</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Echaide</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Koster</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Aquino</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal>
                      <italic>etÂ al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Metabolism of a synthetic compared with a natural therapeutic pulmonary surfactant in adult mice</article-title>
                  <source>
                    <italic>J Lipid Res</italic>
                  </source>
                  <year>2018</year>
                  <volume>59</volume>
                  <fpage>1880</fpage>
                  <lpage>1892</lpage>
                  <pub-id pub-id-type="pmid">30108154</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib7">
                <label>7.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Meng</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Sun</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Lu</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Fu</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Meng</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Scott</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>
                      <italic>etÂ al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Exogenous surfactant may improve oxygenation but not mortality in adult patients with acute lung injury/acute respiratory distress syndrome: a meta-analysis of 9 clinical trials</article-title>
                  <source>
                    <italic>J Cardiothorac Vasc Anesth</italic>
                  </source>
                  <year>2012</year>
                  <volume>26</volume>
                  <fpage>849</fpage>
                  <lpage>856</lpage>
                  <pub-id pub-id-type="pmid">22265270</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib8">
                <label>8.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Roux</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Nakamura</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Sweet</surname>
                      <given-names>AY</given-names>
                    </name>
                    <name>
                      <surname>Gluck</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>The lecithin-sphingomyelin ratio of amniotic fluid: an index of fetal lung maturity?</article-title>
                  <source>
                    <italic>Pediatrics</italic>
                  </source>
                  <year>1972</year>
                  <volume>49</volume>
                  <fpage>464</fpage>
                  <lpage>467</lpage>
                </mixed-citation>
              </ref>
              <ref id="bib9">
                <label>9.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cogo</surname>
                      <given-names>PE</given-names>
                    </name>
                    <name>
                      <surname>Toffolo</surname>
                      <given-names>GM</given-names>
                    </name>
                    <name>
                      <surname>Ori</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Vianello</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Chierici</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gucciardi</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>
                      <italic>etÂ al.</italic>
                    </etal>
                  </person-group>
                  <article-title>Surfactant disaturated-phosphatidylcholine kinetics in acute respiratory distress syndrome by stable isotopes and a two compartment model</article-title>
                  <source>
                    <italic>Respir Res</italic>
                  </source>
                  <year>2007</year>
                  <volume>8</volume>
                  <fpage>13</fpage>
                  <pub-id pub-id-type="pmid">17313681</pub-id>
                </mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
